Scienture Holdings, Inc. revenue
Scienture Holdings, Inc.'s revenue was $431,609 in fiscal 2025, up 215.9% on the year before. Since fiscal 2013 ($955,881) it has grown at a compound -6.4% a year. Over the last twelve months it was $821,315.
Revenue history
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 3 | 2 | 3 | 4 | 7 | 17 | 10 | 10 | 1 | 0 | 0 | 1 |
| Growth on the year before | — | +56.5% | +94.7% | −14.8% | +18.1% | +30.7% | +94.1% | +130.3% | −42.2% | +3.6% | −86.7% | −90.0% | +215.9% | — |
| Gross profit | 0 | 1 | 3 | 2 | 3 | 3 | 5 | 6 | 5 | 6 | 0 | 0 | 0 | 1 |
| Gross margin | 1.2% | 70.6% | 93.5% | 100.0% | 100.0% | 88.3% | 65.5% | 33.3% | 48.0% | 53.8% | 3.6% | 4.4% | 76.8% | 87.7% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Scienture Holdings, Inc. | $821,315 | 540.6% | -58.5% |
| 60 Degrees Pharmaceuticals, Inc. | $1.1m | 73.2% | 74.9% |
| China SXT Pharmaceuticals, Inc. | $1.1m | -34.6% | — |
| Lipocine Inc. | $1.6m | -62.7% | 205.6% |
| Nutriband Inc. | $1.6m | -37.3% | -10.8% |
| Akanda Corp. | $258,075 | -69.2% | — |
Compare with peers
- 60 Degrees Pharmaceuticals, Inc. revenue
- China SXT Pharmaceuticals, Inc. revenue
- Lipocine Inc. revenue
- Nutriband Inc. revenue
- Akanda Corp. revenue
Head to head: SCNX vs SXTPSCNX vs SXTCLPCN vs SCNXAKAN vs SCNX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies